TABLE 2.
Distribution and clinical characteristics of malignancies following kidney transplantation by sex.
| Male patients | Female patients | All | Percentage | Age at transplantation, mean ± SD, y | Age at diagnosis of PTM, mean ± SD, y | Time from transplant to PTM, median (IQR), y | |
|---|---|---|---|---|---|---|---|
| Solid | |||||||
| Urothelial | 11 | 17 | 28 | 35.0 | 49.7 ± 9.93 | 58.7 ± 12.7 | 6.63 (4.55, 10.4) |
| Prostate | 9 | 9 | 11.3 | 56.3 ± 7.22 | 68.8 ± 7.32 | 11.8 (8.70, 13.0) | |
| Liver and bile duct | 5 | 4 | 9 | 11.3 | 46.0 ± 11.2 | 53.5 ± 14.1 | 4.96 (3.15, 9.34) |
| Breast | 8 | 8 | 10.0 | 47.3 ± 7.31 | 53.0 ± 7.92 | 5.72 (2.64, 9.03) | |
| Colorectal | 2 | 4 | 6 | 7.5 | 47.8 ± 9.91 | 62.8 ± 7.80 | 13.0 (12.2, 14.4) |
| Trachea, lung, bronchus | 5 | 1 | 6 | 7.5 | 57.0 ± 6.04 | 61.4 ± 6.73 | 4.67 (3.24, 6.23) |
| Other solid malignancies, unspecified | 1 | 1 | 2 | 2.5 | 54.8 ± 5.59 | 58.7 ± 6.54 | 3.79 (3.12, 4.46) |
| Cervix | 3 | 3 | 3.8 | 57.1 ± 2.77 | 61.5 ± 5.53 | 3.49 (1.89, 7.85) | |
| Gallbladder | 1 | 0 | 1 | 1.3 | 38.6 | 40.5 | 1.96 |
| Kidney | 3 | 0 | 3 | 3.8 | 55.0 ± 6.77 | 62.9 ± 4.29 | 9.36 (4.43, 9.94) |
| Thyroid | 0 | 2 | 2 | 2.5 | 49.6 ± 23.8 | 53.1 ± 21.3 | 3.43 (1.64, 5.22) |
| Stomach | 1 | 0 | 1 | 1.3 | 63.7 | 77.0 | 13.3 |
| Ovary | 1 | 1 | 1.3 | 60.9 | 63.3 | 2.43 | |
| Uterus, part unspecified | 1 | 1 | 1.3 | 35.6 | 47.4 | 11.8 | |
| Total | 38 | 42 | 80 | 100 | |||
| Hematologic | |||||||
| NHL | |||||||
| Monomorphic B cell | 15 | 8 | 23 | 71.9 | 47.1 ± 10.2 | 57.2 ± 11.1 | 11.4 (4.11, 15.4) |
| Polymorphic | 1 | 3 | 4 | 12.5 | 49.0 ± 12.7 | 54.6 ± 11.0 | 4.16 (4.11, 4.57) |
| Monomorphic T cell | 2 | 0 | 2 | 6.3 | 37.3 ± 13.7 | 44.5 ± 19.6 | 4.84 (1.61, 12.7) |
| Leukemia, all types | 1 | 1 | 2 | 6.3 | 54.1 ± 6.52 | 58.4 ± 6.23 | 4.36 (4.16, 4.57) |
| HL | 1 | 0 | 1 | 3.1 | 52.3 | 60.1 | 7.78 |
| Total | 20 | 12 | 32 | 100 | |||
| Skin | |||||||
| SCC | 12 | 4 | 16 | 76.2 | 50.5 ± 7.31 | 63.0 ± 7.02 | 10.7 (7.10, 18.8) |
| BCC | 4 | 1 | 5 | 23.8 | 52.4 ± 14.4 | 62.4 ± 8.73 | 7.62 (3.15, 15.3) |
| Total non-melanoma | 16 | 5 | 21 | 100 | |||
Abbreviations: BCC, basal cell carcinoma; HL, Hodgkin’s lymphoma; IQR, interquartile range; NHL, non-Hodgkin’s lymphoma; PTM, post-transplant malignancy; SCC, squamous cell carcinoma; SD, standard deviation.